We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$7.16B
AUM Growth
+$666M
(+10%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$146M |
| 2 |
Gilead Sciences
GILD
|
+$116M |
| 3 |
Amazon
AMZN
|
+$86.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$84.7M |
| 5 |
Analog Devices
ADI
|
+$80M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$73.2M |
| 2 |
Palo Alto Networks
PANW
|
+$59.8M |
| 3 |
Alkermes
ALKS
|
+$55.3M |
| 4 |
Accenture
ACN
|
+$53.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.05% |
| 2 | Technology | 29.2% |
| 3 | Financials | 8.76% |
| 4 | Industrials | 7.7% |
| 5 | Communication Services | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Ross Stores
ROST
$81B
| $9.75M | 0.14% |
115,673
+39,042
| +51% | +$3.31M |
|
|
IRBT
202
DELISTED
iRobot
IRBT
| $9.68M | 0.14% |
171,900
+158,266
| +1,161% | +$8.31M |
|
|
LGV
203
DELISTED
Longview Acquisition Corp. II
LGV
| $9.67M | 0.14% |
984,500
+659,500
| +203% | +$6.48M |
|
|
AMRN
204
Amarin Corp
AMRN
$295M
| $9.57M | 0.13% |
+438,808
| New | +$11.8M |
|
205
Zymeworks
ZYME
$1.66B
| $9.56M | 0.13% |
1,554,082
-87,794
| -5% | -$529K |
|
206
Bausch Health
BHC
$2.45B
| $9.3M | 0.13% |
1,349,573
| – | – |
|
207
Corcept Therapeutics
CORT
$11.9B
| $9.28M | 0.13% |
+361,974
| New | +$9.69M |
|
|
HERA
208
DELISTED
FTAC Hera Acquisition Corp. Class A Ordinary Shares
HERA
| $9.14M | 0.13% |
921,381
+671,381
| +269% | +$6.62M |
|
209
Pulmonx
LUNG
$86.2M
| $9.14M | 0.13% |
548,512
+116,880
| +27% | +$2.15M |
|
210
Cirrus Logic
CRUS
$6.68B
| $9.12M | 0.13% |
+132,565
| New | +$10.4M |
|
|
GBT
211
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.11M | 0.13% |
133,700
-813,914
| -86% | -$44.9M |
|
|
MRNS
212
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $9.1M | 0.13% |
+1,368,123
| New | +$8.42M |
|
|
FTVI
213
DELISTED
FinTech Acquisition Corp. VI Class A Common Stock
FTVI
| $8.96M | 0.13% |
901,019
+125,000
| +16% | +$1.24M |
|
214
Toast
TOST
$19.5B
| $8.71M | 0.12% |
+520,643
| New | +$9.03M |
|
215
Jazz Pharmaceuticals
JAZZ
$16.1B
| $8.61M | 0.12% |
64,602
-332,259
| -84% | -$50.5M |
|
|
KLRS
216
Kalaris Therapeutics
KLRS
$100M
| $8.58M | 0.12% |
47,265
| – | – |
|
217
TJX Companies
TJX
$174B
| $8.29M | 0.12% |
133,484
+22,583
| +20% | +$1.42M |
|
218
GlobalFoundries
GFS
$28.9B
| $8.27M | 0.12% |
+171,082
| New | +$9.21M |
|
219
Karyopharm Therapeutics
KPTI
$46.7M
| $8.26M | 0.12% |
+100,884
| New | +$7.54M |
|
|
SPLK
220
DELISTED
Splunk Inc
SPLK
| $8.23M | 0.12% |
109,429
+49,950
| +84% | +$4.9M |
|
|
SNRH
221
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
| $8.14M | 0.11% |
818,975
| – | – |
|
222
Planet Fitness
PLNT
$4.39B
| $8.11M | 0.11% |
140,569
+11,380
| +9% | +$820K |
|
223
Roivant Sciences
ROIV
$24.9B
| $8.05M | 0.11% |
+2,499,335
| New | +$9.68M |
|
|
LCAA
224
DELISTED
L Catterton Asia Acquisition Corp Class A Ordinary Shares
LCAA
| $8.03M | 0.11% |
810,400
+10,400
| +1% | +$103K |
|
|
ESPR
225
DELISTED
Esperion Therapeutics
ESPR
| $8.01M | 0.11% |
1,195,705
+351,070
| +42% | +$2.41M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.
- Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
- Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
- Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
- Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
- Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
- Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
- Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.
Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.